Neurosurgical training in Bristol and Nottingham, undertaking a PhD under the supervision of Professor R Grundy examining paediatric high grade gliomas. Appointed clinical associate professor in Neurosurgery, working in the Children's Brain Tumour Research Centre and Nottingham University Hospitals.
My research has involved a diverse array of techniques including cell culture (2d and 3d); molecular analysis of tumour specimens by immunohistochemistry, rt-PCR, FISH and MRS; bio-informatic analysis; microRNA biology; tumour heterogeneity and drug delivery.
Lecturer Graduate Entry Medicince and Cancer Biology courses
BMedSci research project supervisor
My current work examines the effects of microRNAs on angiogenesis and tumour growth. Aberrant patterns of microRNA expression are found in malignant brain tumours in children and these are associated… read more
ALFARDUS, HUDA, MCINTYRE, ALAN and SMITH, STUART, 2017. MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma.: BioMed research international BioMed research international. 2017(4), 9157370-13 DIKSIN, MOHAMMED, SMITH, STUART J and RAHMAN, RUMAN, 2017. The Molecular and Phenotypic Basis of the Glioma Invasive Perivascular Niche. International journal of molecular sciences. 18(11),
SMITH, STUART J, DIKSIN, MOHAMMED, CHHAYA, SAACHI, SAIRAM, SHWETHA, ESTEVEZ-CEBRERO, MARIA A and RAHMAN, RUMAN, 2017. The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour. International journal of molecular sciences. 18(11),
My current work examines the effects of microRNAs on angiogenesis and tumour growth. Aberrant patterns of microRNA expression are found in malignant brain tumours in children and these are associated with many key neoplastic features. We seek to characterise and investigate these networks of altered gene regulation and understand how they relate to the aggressive features seen in these cancers. It may be possible to treat these tumours by utilising microRNA biology to alter the expression of a large number of oncogenes.
Our drug delivery work is focusing on efficacy and toxicity studies of chemotherapy loaded PLGA/PEG material, evaluating different drugs and release profiles to optimise combinations for human use.
We hope to progress current research to examine further the effects of altered cellular metabolism in high grade glioma brain tumours. These tumours exhibit altered cellular energy metabolism as a key part of their neoplastic nature and this is a key driver of angiogenesis and malignant potential. By targeting these pathways it may be possible to affect a broad range of tumour behaviours, possibly through microRNA control.
We are also moving forward with drug delivery solutions, aiming to commence first in man trials within the next few years of drug loaded PLGA/PEG for adult glioblastoma.